Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis

British Journal of Cancer

Volumn 106, Issue 5, 2012, Pages 904-908

  De Martino, M ^a   Hoetzenecker, K ^a   Ankersmit, H J ^a   Roth, G A ^a   Haitel, A ^a   Waldert, M ^a   Klatte, T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

20S proteasome; diagnosis; hypoxia; prognosis; renal cancer

Indexed keywords

20S PROTEASOME; PROTEASOME; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SYMPTOM; TREATMENT RESPONSE; TUMOR NECROSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857787712     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.20     Document Type: Article

References (31)

1. Corn PG (2007) Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem 8: S4
2. de Martino M, Klatte T, Haitel A, Marberger M (2012) Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 118: 82-90
3. Egerer K, Kuckelkorn U, Rudolph PE, Ruckert JC, Dorner T, Burmester GR, Kloetzel PM, Feist E (2002) Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 29: 2045-2052
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917
5. Ficarra V, Martignoni G, Lohse C, Novara G, Pea M, Cavalleri S, Artibani W (2006) External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 175: 1235-1239
6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 168: 2395-2400 (Pubitemid 35402623)
7. Gore ME, Larkin JM (2011) Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 104: 399-406
8. Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14: 451-456 (Pubitemid 43363478)
9. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J, Wohlschlaeger J, Sixt SU (2011) The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol 120: 233-238
10. Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer S, Kimmig R, Wohlschlaeger J, Sixt SU (2011) Circulating 20S proteasome in patients with non-metastasized breast cancer. Anticancer Res 31: 2197-2201
11. Jakob C, Egerer K, Liebisch P, Turkmen S, Zavrski I, Kuckelkorn U, Heider U, Kaiser M, Fleissner C, Sterz J, Kleeberg L, Feist E, Burmester GR, Kloetzel PM, Sezer O (2007) Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 109: 2100-2105 (Pubitemid 46348211)
12. Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N, Ichihara A (1991) Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 51: 6677-6685
13. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25: 1316-1322 (Pubitemid 46706877)
14. Klatte T, Bohm M, Nelius T, Filleur S, Reiher F, Allhoff EP (2007a) Evaluation of peri-operative peripheral and renal venous levels of pro-and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU Int 100: 209-214 (Pubitemid 46878551)
15. Klatte T, Pantuck AJ (2008) Molecular biology of renal cortical tumors. Urol Clin North Am 35: 573-580
16. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS (2007b) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13: 7388-7393
17. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22: 3720-3725 (Pubitemid 41095212)
18. Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF, Bureau JP (2001) Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer 92: 2493-2500 (Pubitemid 33049430)
19. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180: 510-514
20. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, Sinescu IC (2007) Renal cell carcinoma guideline. Eur Urol 51: 1502-1510 (Pubitemid 46634775)
21. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naimi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S (2010) Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 5: e10715
22. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T (2011) Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 104: 741-745
23. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E (2011) Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 104: 1256-1261
24. Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Hoetzenecker K, Boltz-Nitulescu G, Ankersmit HJ (2005) Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest 35: 399-403 (Pubitemid 40826839)
25. Sobin LH, Gospodarowicz MK, Wittekind C (2009) Urological tumours-kidney. In TNM Classification of Malignant Tumours 7th edn, pp 255-257. Wiley-Blackwell: Oxford
26. Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP, Meunier L (2005) High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol 152: 948-953 (Pubitemid 40704935)
27. Szerafin T, Hoetzenecker K, Hacker S, Horvath A, Pollreisz A, Arpad P, Mangold A, Wliszczak T, Dworschak M, Seitelberger R, Wolner E, Ankersmit HJ (2008) Heat shock proteins 27, 60, 70, 90alpha, and 20S proteasome in on-pump versus off-pump coronary artery bypass graft patients. Ann Thorac Surg 85: 80-87 (Pubitemid 350265792)
28. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP (2008) Serumsoluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 68: 6054-6058
29. Tisdale MJ (2003) Pathogenesis of cancer cachexia. J Support Oncol 1: 159-168
30. Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068 (Pubitemid 29449214)
31. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, DeKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566 (Pubitemid 35402959)